StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for NSPR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.17 | $1.14 | -2.56% | 0.2M |
| 05-15 | $1.13 | $1.05 | -7.08% | 0.2M |
| 05-18 | $1.05 | $1.05 | +0.00% | 0.1M |
| 05-19 | $1.05 | $1.00 | -4.76% | 0.3M |
| 05-20 | $1.00 | $1.00 | +0.00% | 0.2M |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.40M | $8.98M | $5.83M | $3.31M |
Operating Income | $-13.98M | $-49.61M | $-37.53M | $-24.48M |
Net Income | $-13.69M | $-48.79M | $-37.02M | $-24.32M |
EPS (Diluted) | $-0.16 | $-0.76 | $-0.64 | $-0.48 |
Total Assets | $56.47M | $69.40M | $78.47M | $33.34M |
Total Liabilities | $12.85M | $14.20M | $14.36M | $13.10M |
Cash & Equivalents | $11.36M | $8.94M | $63.40M | $11.51M |
Free Cash Flow OCF − CapEx | $-12.53M | $-36.77M | $-27.02M | $-18.06M |
Shares Outstanding | 46.84M | 43.53M | 41.92M | 32.55M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.